Cryoablation With Vestibular Expansion for the Treatment of Paroxysmal/Short-course Persistent Atrial Fibrillation

Inclusion Criteria: 1. 18 years old ≤ age ≤ 85 years old; 2. Patients with paroxysmal/short-term persistent atrial fibrillation; 3. Be able to understand the purpose of the research, voluntarily participate in the research and sign the informed consent. Exclusion Criteria: 1. Echocardiography shows that the left atrium diameter is greater than or equal to 45mm; 2. Preoperative CT or esophageal echocardiography suggests that there is a thrombus in the left atrium/left atrial appendage; 3. Those who have undergone left atrial ablation or left atrial surgery; 4. Those who have received simple left atrial appendage occlusion; 5. New York heart function class (NYHA) class III or IV congestive heart failure or LVEF (%) less than 40%; 6. Those who have undergone valve repair; 7. Preoperative electrocardiogram or Holter confirmed the presence of typical atrial flutter or other supraventricular tachycardia (holding The duration is greater than 30 s); 8. Secondary atrial fibrillation, including uncontrolled hyperthyroidism, acute alcoholism, cardiac surgery postoperative atrial fibrillation, etc.; 9. History of acute coronary events or percutaneous coronary stent intervention within 6 months before enrollment; 10. Those with a history of cardioverter-defibrillator (ICD) implantation or a history of cardiac resynchronization therapy (CRT); 11. History of stroke or transient ischemic attack within 6 months before enrollment; 12. Those with obvious bleeding tendency who cannot receive postoperative systemic anticoagulation; 13. Severe structural heart disease, including moderate to severe mitral insufficiency or stenosis, previous myocardial infarction, hypertrophic cardiomyopathy, etc.; 14. Combined with other serious diseases, the life expectancy is less than 12 months; 15. Women who are pregnant, breastfeeding and planning to become pregnant; 16. Have participated in or are participating in clinical investigators of other drugs or devices within 3 months before enrollment; 17. Other conditions assessed by the investigator to be unsuitable for inclusion in this study, such as persons with mental disorders or mental disorders.